Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Read full release

Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment

Read full release

Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China

Read full release

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Read full release

Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV

Read full release

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Read full release

Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO

Read full release

Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Read full release